Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : IT CAME FROM OUTER SPACE -- Ignore unavailable to you. Want to Upgrade?

To: Solon who wrote (174)	2/26/1999 5:25:00 PM
From: Don Pueblo	Read Replies (2) \| Respond to of 480

Yeah, there was some news on that some time back. Some pet psychiatrists or some such nonsense. It inflamed me at the time, I might have posted about it on the cOUSIN SHORTY thread, I don't recall. What astounding arrogance those evil bastards have. Feeding drugs to cats and dogs. Anyone with once ounce of brain matter can see they are just trying to sell drugs. Don't get me started on this, I have strong opinions.

To: Solon who wrote (174)	2/26/1999 5:58:00 PM
From: kinkblot	Read Replies (1) \| Respond to of 480

Anipryl (selegiline; 1-deprenyl)? draxis.com I once owned shares in Deprenyl Research Ltd. / Deprenyl Animal Health Inc. DEPLF('87)/DAHI('91)--->Draxis(renamed '94)/DAHI---+Pfizer(rights). The original target for deprenyl was the treatment of Parkinson's in humans. The former Chairman of the company, Dr. Morton Shulman, had that disease. It is sold under the brand name Eldepryl by Draxis and others. They get the 1-deprenyl from the Hungarian company Chinoin that developed it. Some also believe the drug has potential to increase life expectancy. They later extended the patient pool from people and lab rats to include household pets. I believe it's basically the same stuff. The DAHI IPO was in 1991, so it took ~7 years for approval, much longer than they expected. This is from the 1996 Form 20-F on Draxis' website: Canadian Pharmaceutical Unit / Products Being Marketed Eldepryl® is a selective monoanimine oxidase-type B ("MAO-B") inhibitor and is used in the treatment of Parkinson's disease. MAO-B is an enzyme that degrades the structure of certain compounds, such as dopamine, which regulate various physiological functions, including certain aspects of central nervous system activity. Dopamine is a neurotransmitter which facilitates movement, posture, balance and walking. Eldepryl® has several common or generic names, including selegiline hydrochloride, selegiline and l-deprenyl. In addition to being marketed by the Company in Canada, Eldepryl® is marketed by others in Switzerland, Sweden, France, Finland, Germany, Hungary, Italy, the United Kingdom, and the United States and other countries for the treatment of Parkinson's disease. Eldepryl® is also marketed in Italy for the treatment of Alzheimer's disease. The Somerset division of Mylan Labs also sells it. Product labeling: eldepryl.com Bonus: Fido's protected against the 'cheese reaction'!